Alcohol DrinkingJBNCT07588022
Acute Effects of Jägermeister With Energy Drinks (Jägermbomb)
A study testing Jägermeister and Energy Drink (Jägerbomb) in people with Alcohol Drinking and Healthy Adult Participants, run by Fundació Institut Germans Trias i Pujol at 1 site in Spain.
Trial summary
The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Alcohol Drinking, Healthy Adult Participants, Binge Alcohol Consumption
- What is being tested?
- Jägermeister and Energy Drink (Jägerbomb)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteSpain
- Study dates
- 18 Feb 2026to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men and women between 18-45 years old with a weight between 50-90 kg for men and between 55-80 kg for women, and a body mass index (BMI) between 19-28 kg/m2. Lower or higher weights or BMIs are allowed, in the opinion of the Principal Investigator or the collaborators designated by the Principal Investigator and that do not pose a risk to the subjects and do not interfere with the objectives of the study.
- Alcohol consumption in the form of occasional binge drinking (≥1 time/month), social alcohol consumption (≥10g/day distributed weekly) and experience in alcohol intoxication.
- Consumption ≥7 drinks with methylxanthines (coffee, tea, chocolate, cola, BE) per week and who have consumed ED on at least one occasion.
- Understand and agree to the trial procedures and sign an informed consent.
- History and physical examination that demonstrate no organic or psychiatric disorders.
- The ECG and general blood and urine tests performed before the test should be within normal limits. Minor or punctual variations from the limits of normality are allowed if, at the discretion of the Principal Investigator, taking into account the state of science, they are not of clinical significance, do not pose a risk to the subjects and do not interfere with the assessment of the product. These variations and their non-relevance will be justified in writing in a specific way.
Who cannot join
- Not meeting the inclusion criteria.
- History or clinical evidence of gastrointestinal, liver, renal or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.
- Current history of substance use disorder according to DSM-V (except nicotine). A previous history of mild substance use disorder (corresponding to substance abuse according to DSM-IV criteria) is admitted.
- History or clinical evidence of psychiatric disorders, alcoholism, abuse of drugs or other drugs or habitual consumption of psychoactive drugs.
- Have participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks.
- 5) Have suffered any organic disease or major surgery in the three months prior to the start of the study.
Show all 13Show fewer
- 6) Subjects who have an intolerance or have had serious adverse reactions to alcohol. The inclusion of subjects of oriental origin who do not have an intolerance to alcohol will be allowed.
- 7) Have taken medication regularly in the month prior to the study sessions, with the exception of vitamins, herbal remedies, or dietary supplements that, in the judgment of the Principal Investigator or collaborators designated by the Principal Investigator, do not pose a risk to the subjects and do not interfere with the objectives of the study. Treatment with single doses of symptomatic medication in the week prior to study sessions will not be grounds for exclusion if it is assumed to have been completely eliminated on the day of the experimental session.
- 8) Smokers of >5 cigarettes a day. 9) Consumption of more than 20 g of alcohol daily in women and more than 40 g in men.
- 10) Consumers of more than 5 coffees, teas, colas, or other stimulant or xanthine beverages daily in the 3 months prior to the start of the study.
- 11) Subjects who are not able to understand the nature of the trial and the procedures they are asked to follow.
- 12) Subjects with positive serology for hepatitis B, C or HIV. 13) Women who are pregnant or breastfeeding, or who use hormonal contraceptives or do not use reliable contraceptive measures during the study (such as abstinence, intrauterine devices, barrier methods or with a vasectomized partner).
- 14) Women with amenorrhea or premenstrual syndrome of severe intensity.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Hospital Universitari Germans Trias i Pujol-IGTP
Barcelona
Soraya Martín Sánchez, Mrs, +34934973831, smartins.mn.ics@gencat.cat
Clara Pérez-Mañá, MD, PhD
About this study
Official title: Acute Effects of an Explosive Cocktail With Energy Drinks That is Trendy Among Young People, the Jägerbomb
The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Secondary objectives are to assess whether Jägerbombs produce prototypical alcohol effects, increase stimulation and rewarding effects, affect coordination, time reaction and vision, change stress-related hormone responses, and cause hangover symptoms.
Read the detailed description
Alcohol use is very common among young people in Spain. Binge drinking is a pattern of alcohol consumption that raises blood alcohol concentration (BAC) to 0.08% or higher (0.4 mg/L in breath air), typically defined as drinking 5 or more standard drinks for men or 4 or more for women within about 2 hours.This is a serious public health problem because it can cause illness, injuries, and even death.
Energy drinks (ED) are also widely used by young people and are often mixed with alcohol. People do this to hide the taste of alcohol or to feel less tired or drunk. However, ED do not reduce alcohol intoxication and are linked to more risky behavior. Research suggests that ED only slightly reduce some alcohol-related problems, such as slower reactions. This can give a false feeling of safety and make people more likely to drive while drunk.
One popular mixture is the Jägerbomb, a combination of Jägermeister liquor and energy drink (ED), but its effects have not been previously studied.
This study will be conducted as a randomized, double-blind, placebo-controlled trial in healthy adults who have experience consuming alcohol and caffeinated beverages.
A pilot study has been conducted in the first four participants (two women and two men) using a dose of 55 g of alcohol.
- Being tested
- Jägermeister and Energy Drink (Jägerbomb), Jägermeister and Energy Drink Placebo, Alcohol Placebo and Energy Drink Placebo
- Keywords
- Binge drinking, Jägerbomb, Alcohol, Psychomotor performance
- Medical subject headings
- Alcohol Drinking, Binge Drinking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Jägermeister and Energy Drink (Jägerbomb)Dietary supplement
Multiple oral dose of Jägermeister mixed with ED
Jägermeister and Energy Drink PlaceboDietary supplement
Multiple oral dose of Jägermeister mixed with a placebo of ED (non-caffeinated soft drink)
Alcohol Placebo and Energy Drink PlaceboDietary supplement
Multiple oral dose of alcohol placebo (water) mixed with ED placebo (non-caffeinated soft drink)
| Study group | Role | What they receive |
|---|---|---|
| Alcohol (Jägermeister) and Energy Drink: Jägerbomb | Experimental | The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (ethanol 55 g) + ED 625 ml (200 mg caffeine). Men: Jägermeister 250 mL (ethanol 70 g) + ED 625 ml (200 mg caffeine) Receives: Dietary Supplement: Jägermeister and Energy Drink (Jägerbomb) |
| Alcohol (Jägermeister) and Energy Drink Placebo | Active comparator | The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (55 g of ethanol) + placebo ED (a non-caffeinated soft drink) 625 mL. Men: Jägermeister 250 mL (70 g) + placebo ED (a non-caffeinated soft drink) 625 mL. Receives: Dietary Supplement: Jägermeister and Energy Drink Placebo |
| Alcohol placebo and Energy Drink Placebo | Placebo comparator | The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL. Men: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL. Receives: Dietary Supplement: Alcohol Placebo and Energy Drink Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in reaction time (Psychomotor Vigilance Task)
Test will be performed using a computer program. Mean and median latency will be assessed. Obtained baseline, 1.5 and 4-h after administration.
Measured: From baseline to 4 hours after administration
Secondary outcomes (29)
Maximum concentration (Cmax) of ethanol in breath air
Maximum concentration (Cmax) of ethanol in breath air
Measured: From baseline to 8 hours after administration
Maximum concentration (Cmax) of caffeine in oral fluid
Maximum concentration (Cmax) of caffeine in oral fluid
Measured: From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations
Obtained baseline and 0.17, 0.33 , 0.5, 0.66, 0,83, 1, 1.25, 1.5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Area under the concentration-time curve (AUC 0-6h) of caffeine oral fluid concentrations
Calculation of AUC of caffeine concentrations obtained baseline and 1, 1.5, 2, 4, 6-h after administration.
Measured: From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of ethanol in breath air
Time to reach maximum concentration (tmax) of ethanol in breath air
Measured: From baseline to 8 hours after administration
Time to reach maximum concentration (tmax) of caffeine in oral fluid
Time to reach maximum concentration (tmax) of caffeine in oral fluid
Measured: From baseline to 6 hours after administration
Maximum concentration (Cmax) of cortisol in oral fluid
Maximum concentration (Cmax) of cortisol in oral fluid
Measured: From baseline till 6 hours after administration
Time to reach maximum concentration (tmax) of saliva in oral fluid
Time to reach maximum concentration (tmax) of saliva in oral fluid
Measured: From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-6h) of cortisol concentrations in oral fluid
Calculation of AUC of cortisol oral fluid concentrations. Obtained baseline and 1, 1.5 , 2, 4, 6-h after administration.
Measured: From baseline till 6 hours after administration
Change in visual acuity
A computer program will be used to measure static and dynamic visual acuity with different contrast (100% and 10%) at baseline, 2 and 4-h after administration
Measured: From baseline to 4 hours after administration
Change in unstable tracking task
Test will be performed using a computer program. Mean lambda and number of errors will be measured. Obtained baseline and 1.5, 4-h after administration.
Measured: From baseline to 4 hours after administration
Change in pupillary diameter
Pupillary diameter will be measured with a manual pupilometer
Measured: From baseline to 4 hours after administration
Change in drowsiness feeling
Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in drunkenness feeling
Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration
Measured: From baseline to 8 hours after administration
Change in dizziness feeling
Dizziness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration
Measured: From baseline to 8 hours after administration
Change in palpitations reported by the participant
Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in anxiety feeling
Anxiety will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in headache
Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.5, 1, 1.5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in ability and predisposition to drive in certain situations
Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.5, 4, 6-h after administration.
Measured: From baseline to 6 hours after administration
Desire to keep drinking
Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.5 hours.
Measured: At 1.5 hours after administration
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Obtained baseline and 1, 2, 4, 6 and 8-h after administration
Measured: From baseline to 8 hours after administration
Change in blood pressure
Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in heart rate
Heart rate (bpm) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in oral temperature
Oral temperature (ºC) will be measured obtained baseline and 0.5, 1, 1,5, 2, 3, 4, 6 and 8-h after administration.
Measured: From baseline to 8 hours after administration
Change in Maddox Wing score (MW)
Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.5, 4-h after administration.
Measured: From baseline to 4 hours after administration
Hangover
Measured at 8 and 12h , with Alcohol Hangover Severity Scale
Measured: At 8 hours and 12 hours after administration
Change in anxiety
Measured with Anxiety-state scale (STAI-S) at baseline, 1,1,4, 6-h after administration
Measured: From baseline to 6 hours after administration
Beverage identification
Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration
Measured: At 8 hours after administration
Urine volume generated
Mililiters of urine collected
Measured: From baseline to 8 hours after administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start18 Feb 2026
- Primary completionMar 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Alcohol DrinkingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundació Institut Germans Trias i Pujol
- Sponsor type
- University, hospital or other
- Collaborators
- Plan Nacional sobre Drogas
- Responsible party
- Sponsor
- Investigators
- Clara Pérez Mañá, MD, PhD, Principal investigator, Hospital Universitari Germans Trias i Pujol-IGTP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07588022
- Sponsor's protocol ID
- HGTP/JB/PNSD/1
- Other IDs
- 2024I013
- Acronym
- JB
- Status last verified
- Apr 2026
- First submitted
- 4 May 2026
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared as the dataset is subject to ongoing analyses and planned future publications.
Publications
Mets MA, Ketzer S, Blom C, van Gerven MH, van Willigenburg GM, Olivier B, Verster JC. Positive effects of Red Bull(R) Energy Drink on driving performance during prolonged driving. Psychopharmacology (Berl). 2011 Apr;214(3):737-45. doi: 10.1007/s00213-010-2078-2. Epub 2010 Nov 10.
PubMed 21063868White WL. Erratum to: Why I hate the index finger. Hand (N Y). 2011 Jun;6(2):233. doi: 10.1007/s11552-011-9321-0. Epub 2011 Mar 18.
PubMed 21776199Redondo B, Vera J, Carreno-Rodriguez C, Molina-Romero R, Jimenez R. Acute Effects of Caffeine on Dynamic Accommodative Response and Pupil Size: A Placebo-controlled, Double-blind, Balanced Crossover Study. Curr Eye Res. 2020 Sep;45(9):1074-1081. doi: 10.1080/02713683.2020.1725060. Epub 2020 Feb 11.
PubMed 32011181McKetin R, Coen A, Kaye S. A comprehensive review of the effects of mixing caffeinated energy drinks with alcohol. Drug Alcohol Depend. 2015 Jun 1;151:15-30. doi: 10.1016/j.drugalcdep.2015.01.047. Epub 2015 Feb 24.
PubMed 25861944Liguori A, Robinson JH. Caffeine antagonism of alcohol-induced driving impairment. Drug Alcohol Depend. 2001 Jul 1;63(2):123-9. doi: 10.1016/s0376-8716(00)00196-4.
PubMed 11376916Garrisson H, Scholey A, Verster JC, Shiferaw B, Benson S. Effects of alcohol intoxication on driving performance, confidence in driving ability, and psychomotor function: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2022 Dec;239(12):3893-3902. doi: 10.1007/s00213-022-06260-z. Epub 2022 Nov 2.
PubMed 36322184Howland J, Rohsenow DJ, Arnedt JT, Bliss CA, Hunt SK, Calise TV, Heeren T, Winter M, Littlefield C, Gottlieb DJ. The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time. Addiction. 2011 Feb;106(2):335-41. doi: 10.1111/j.1360-0443.2010.03219.x. Epub 2010 Dec 6.
PubMed 21134017Perez-Mana C, Mateus JA, Diaz-Pellicer P, Diaz-Baggerman A, Perez M, Pujadas M, Fonseca F, Papaseit E, Pujol J, Langohr K, de la Torre R. Effects of Mixing Energy Drinks With Alcohol on Driving-Related Skills. Int J Neuropsychopharmacol. 2022 Jan 12;25(1):13-25. doi: 10.1093/ijnp/pyab051.
PubMed 34338762Hladun O, Papaseit E, Poyatos L, Martin S, Perez-Acevedo AP, Barriocanal AM, Bustos-Cardona T, Malumbres S, De La Torre R, Langohr K, Farre M, Perez-Mana C. No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode. Front Pharmacol. 2025 May 23;16:1581229. doi: 10.3389/fphar.2025.1581229. eCollection 2025.
PubMed 40487410
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Effects of an Explosive Cocktail With Energy Drinks That is Trendy Among Young People, the Jägerbomb
- ClinicalTrials.gov ID
- NCT07588022
- Acronym / sponsor ID
- JB / HGTP/JB/PNSD/1
- Keywords
- Binge drinking, Jägerbomb, Alcohol, Psychomotor performance
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Fundació Institut Germans Trias i PujolUniversity, hospital or other
- Collaborators
- Plan Nacional sobre Drogas
- Study start
- 18 Feb 2026 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to compare the acute effects of drinking Jägerbombs with drinking alcohol alone during a binge-drinking episode, which involves consuming a large amount of alcohol in a short period of time to become intoxicated. Secondary objectives are to assess whether Jägerbombs produce prototypical alcohol effects, increase stimulation and rewarding effects, affect coordination, time reaction and vision, change stress-related hormone responses, and cause hangover symptoms.
Detailed description
Alcohol use is very common among young people in Spain. Binge drinking is a pattern of alcohol consumption that raises blood alcohol concentration (BAC) to 0.08% or higher (0.4 mg/L in breath air), typically defined as drinking 5 or more standard drinks for men or 4 or more for women within about 2 hours.This is a serious public health problem because it can cause illness, injuries, and even death.
Energy drinks (ED) are also widely used by young people and are often mixed with alcohol. People do this to hide the taste of alcohol or to feel less tired or drunk. However, ED do not reduce alcohol intoxication and are linked to more risky behavior. Research suggests that ED only slightly reduce some alcohol-related problems, such as slower reactions. This can give a false feeling of safety and make people more likely to drive while drunk.
One popular mixture is the Jägerbomb, a combination of Jägermeister liquor and energy drink (ED), but its effects have not been previously studied.
This study will be conducted as a randomized, double-blind, placebo-controlled trial in healthy adults who have experience consuming alcohol and caffeinated beverages.
A pilot study has been conducted in the first four participants (two women and two men) using a dose of 55 g of alcohol.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Alcohol (Jägermeister) and Energy Drink: Jägerbomb | Experimental | Dietary Supplement: Jägermeister and Energy Drink (Jägerbomb)The total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (ethanol 55 g) + ED 625 ml (200 mg caffeine). Men: Jägermeister 250 mL (ethanol 70 g) + ED 625 ml (200 mg caffeine) |
| Alcohol (Jägermeister) and Energy Drink Placebo | Active comparator | Dietary Supplement: Jägermeister and Energy Drink PlaceboThe total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Jägermeister 196 mL (55 g of ethanol) + placebo ED (a non-caffeinated soft drink) 625 mL. Men: Jägermeister 250 mL (70 g) + placebo ED (a non-caffeinated soft drink) 625 mL. |
| Alcohol placebo and Energy Drink Placebo | Placebo comparator | Dietary Supplement: Alcohol Placebo and Energy Drink PlaceboThe total volume of drink is 821 mL in women and 875 mL in men, and is divided into 5 doses simulating a binge pattern, administered every 10 min (total time 45 minutes). Women: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL. Men: Ethanol placebo (water) + ED placebo (a non-caffeinated soft drink) 625 mL. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Men and women between 18-45 years old with a weight between 50-90 kg for men and between 55-80 kg for women, and a body mass index (BMI) between 19-28 kg/m2. Lower or higher weights or BMIs are allowed, in the opinion of the Principal Investigator or the collaborators designated by the Principal Investigator and that do not pose a risk to the subjects and do not interfere with the objectives of the study.
- Alcohol consumption in the form of occasional binge drinking (≥1 time/month), social alcohol consumption (≥10g/day distributed weekly) and experience in alcohol intoxication.
- Consumption ≥7 drinks with methylxanthines (coffee, tea, chocolate, cola, BE) per week and who have consumed ED on at least one occasion.
- Understand and agree to the trial procedures and sign an informed consent.
- History and physical examination that demonstrate no organic or psychiatric disorders.
Key exclusion criteria (13 listed)
- Not meeting the inclusion criteria.
- History or clinical evidence of gastrointestinal, liver, renal or other disorders that may involve an alteration in the absorption, distribution, metabolism or excretion of the drug, or that are suggestive of gastrointestinal irritation by drugs.
- Current history of substance use disorder according to DSM-V (except nicotine). A previous history of mild substance use disorder (corresponding to substance abuse according to DSM-IV criteria) is admitted.
- History or clinical evidence of psychiatric disorders, alcoholism, abuse of drugs or other drugs or habitual consumption of psychoactive drugs.
- Have participated in clinical trials with drugs or nutraceuticals in the previous 12 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Jägermeister and Energy Drink (Jägerbomb)Multiple oral dose of Jägermeister mixed with ED | Dietary supplement | Alcohol (Jägermeister) and Energy Drink: Jägerbomb |
| Jägermeister and Energy Drink PlaceboMultiple oral dose of Jägermeister mixed with a placebo of ED (non-caffeinated soft drink) | Dietary supplement | Alcohol (Jägermeister) and Energy Drink Placebo |
| Alcohol Placebo and Energy Drink PlaceboMultiple oral dose of alcohol placebo (water) mixed with ED placebo (non-caffeinated soft drink) | Dietary supplement | Alcohol placebo and Energy Drink Placebo |
Primary outcome
Change in reaction time (Psychomotor Vigilance Task)
Time frame: From baseline to 4 hours after administration
Test will be performed using a computer program. Mean and median latency will be assessed. Obtained baseline, 1.5 and 4-h after administration.
29 secondary outcomes
Maximum concentration (Cmax) of ethanol in breath air
Time frame: From baseline to 8 hours after administration
Maximum concentration (Cmax) of caffeine in oral fluid
Time frame: From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations
Time frame: From baseline to 8 hours after administration
Area under the concentration-time curve (AUC 0-6h) of caffeine oral fluid concentrations
Time frame: From baseline to 6 hours after administration
Time to reach maximum concentration (tmax) of ethanol in breath air
Time frame: From baseline to 8 hours after administration
Time to reach maximum concentration (tmax) of caffeine in oral fluid
Time frame: From baseline to 6 hours after administration
Maximum concentration (Cmax) of cortisol in oral fluid
Time frame: From baseline till 6 hours after administration
Time to reach maximum concentration (tmax) of saliva in oral fluid
Time frame: From baseline to 6 hours after administration
Area under the concentration-time curve (AUC 0-6h) of cortisol concentrations in oral fluid
Time frame: From baseline till 6 hours after administration
Change in visual acuity
Time frame: From baseline to 4 hours after administration
Change in unstable tracking task
Time frame: From baseline to 4 hours after administration
Change in pupillary diameter
Time frame: From baseline to 4 hours after administration
Change in drowsiness feeling
Time frame: From baseline to 8 hours after administration
Change in drunkenness feeling
Time frame: From baseline to 8 hours after administration
Change in dizziness feeling
Time frame: From baseline to 8 hours after administration
Change in palpitations reported by the participant
Time frame: From baseline to 8 hours after administration
Change in anxiety feeling
Time frame: From baseline to 8 hours after administration
Change in headache
Time frame: From baseline to 8 hours after administration
Change in ability and predisposition to drive in certain situations
Time frame: From baseline to 6 hours after administration
Desire to keep drinking
Time frame: At 1.5 hours after administration
Change in subjective effects measured with Addiction Research Center Inventory (ARCI)
Time frame: From baseline to 8 hours after administration
Change in blood pressure
Time frame: From baseline to 8 hours after administration
Change in heart rate
Time frame: From baseline to 8 hours after administration
Change in oral temperature
Time frame: From baseline to 8 hours after administration
Change in Maddox Wing score (MW)
Time frame: From baseline to 4 hours after administration
Hangover
Time frame: At 8 hours and 12 hours after administration
Change in anxiety
Time frame: From baseline to 6 hours after administration
Beverage identification
Time frame: At 8 hours after administration
Urine volume generated
Time frame: From baseline to 8 hours after administration
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Background: PubMed 21063868Mets MA, Ketzer S, Blom C, van Gerven MH, van Willigenburg GM, Olivier B, Verster JC. Positive effects of Red Bull(R) Energy Drink on driving performance during prolonged driving. Psychopharmacology (Berl). 2011 Apr;214(3):737-45. doi: 10.1007/s00213-010-2078-2. Epub 2010 Nov 10.
- Background: PubMed 21776199White WL. Erratum to: Why I hate the index finger. Hand (N Y). 2011 Jun;6(2):233. doi: 10.1007/s11552-011-9321-0. Epub 2011 Mar 18.
- Background: PubMed 32011181Redondo B, Vera J, Carreno-Rodriguez C, Molina-Romero R, Jimenez R. Acute Effects of Caffeine on Dynamic Accommodative Response and Pupil Size: A Placebo-controlled, Double-blind, Balanced Crossover Study. Curr Eye Res. 2020 Sep;45(9):1074-1081. doi: 10.1080/02713683.2020.1725060. Epub 2020 Feb 11.
- Background: PubMed 25861944McKetin R, Coen A, Kaye S. A comprehensive review of the effects of mixing caffeinated energy drinks with alcohol. Drug Alcohol Depend. 2015 Jun 1;151:15-30. doi: 10.1016/j.drugalcdep.2015.01.047. Epub 2015 Feb 24.
- Background: PubMed 11376916Liguori A, Robinson JH. Caffeine antagonism of alcohol-induced driving impairment. Drug Alcohol Depend. 2001 Jul 1;63(2):123-9. doi: 10.1016/s0376-8716(00)00196-4.
- Background: PubMed 36322184Garrisson H, Scholey A, Verster JC, Shiferaw B, Benson S. Effects of alcohol intoxication on driving performance, confidence in driving ability, and psychomotor function: a randomized, double-blind, placebo-controlled study. Psychopharmacology (Berl). 2022 Dec;239(12):3893-3902. doi: 10.1007/s00213-022-06260-z. Epub 2022 Nov 2.
- Background: PubMed 21134017Howland J, Rohsenow DJ, Arnedt JT, Bliss CA, Hunt SK, Calise TV, Heeren T, Winter M, Littlefield C, Gottlieb DJ. The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time. Addiction. 2011 Feb;106(2):335-41. doi: 10.1111/j.1360-0443.2010.03219.x. Epub 2010 Dec 6.
- Background: PubMed 34338762Perez-Mana C, Mateus JA, Diaz-Pellicer P, Diaz-Baggerman A, Perez M, Pujadas M, Fonseca F, Papaseit E, Pujol J, Langohr K, de la Torre R. Effects of Mixing Energy Drinks With Alcohol on Driving-Related Skills. Int J Neuropsychopharmacol. 2022 Jan 12;25(1):13-25. doi: 10.1093/ijnp/pyab051.
- Background: PubMed 40487410Hladun O, Papaseit E, Poyatos L, Martin S, Perez-Acevedo AP, Barriocanal AM, Bustos-Cardona T, Malumbres S, De La Torre R, Langohr K, Farre M, Perez-Mana C. No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode. Front Pharmacol. 2025 May 23;16:1581229. doi: 10.3389/fphar.2025.1581229. eCollection 2025.
- Individual participant dataSharing planned: No. IPD will not be shared as the dataset is subject to ongoing analyses and planned future publications.
Related trials for Alcohol Drinking
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingPhase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
RecruitingPhase 2
Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder
Alcohol Use Disorder
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clara Pérez Mañá, MD, PhD principal investigator
Hospital Universitari Germans Trias i Pujol-IGTP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Jägermeister and Energy Drink (Jägerbomb) in people with Alcohol Drinking and Healthy Adult Participants, run by Fundació Institut Germans Trias i Pujol at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clara Pérez-Mañá, MD, PhD (+34934978865, cperezm.mn.ics@gencat.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in reaction time (Psychomotor Vigilance Task) (time frame: From baseline to 4 hours after administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07588022, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.